The Aussie healthcare stock outpacing rivals with near 700% returns
Shares in Australian healthcare firm Avita Medical rose 696% during 2019 and have risen 23% since the start of 2020.
The stock develops and markets regenerative medical products, particularly a spray-on skin used for burns patients known as RECELL which was approved by the US Food & Drug Administration (FDA) in September, 2018.
It was admitted to the ASX 200 in November, 2019 which it said was a “testament to the company’s solid growth trajectory following the commercialisation of the RECELL System combined with the strength of our de-risked pipeline of future indications beyond burns.”.
Its performance compared to returns of 23.4% by the ASX 200 during 2019 and 7.3% since the start of 2020, according to FE Analytics.
In the firm’s half-year results for the six months to 31 December, 2019, the firm said it may have the opportunity to take part in an FDA registration study on vitiligo and would be focusing more on burns and on trauma and soft tissue injuries.
Total revenue for the period was $13.5 million, more than double the $6.9 million reported for the same period in 2018 with the majority of product sales coming from the US after a successful launch of RECELL in January, 2019.
Performance of Avita Medical over the 12 months to 31 December, 2019 versus ASX 200
AUTHOR
Laura Dew
Recommended for you
Evidentia Group has announced the appointment of a chief risk and operating officer, rounding out its executive leadership team after a slew of hires last month.
Family office Lederer Group has progressed its takeover bid for the Elanor Commercial Property Fund, lodging a bidder’s statement with ASIC as it says the fund has been “unable to agree” on negotiation terms.
Magellan Financial Group is keen to enact further strategic expansions with income from strategic partnerships tripling to $31.1 million from the addition of Vinva during FY25.
Outflows have doubled in the property and infrastructure space to $1.3 billion with advisers instead favouring private markets as Morningstar data finds active property funds are struggling to outperform.
